Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K. Galkina, E. Nosova, M. Krasnova (Moscow, Russian Federation). Modern molecular direct tests for rapid identification and drug susceptibility testing of Mycobacterium tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 1418

Member's Comments

No comment yet.

Related content which might interest you: When will genetic testing replace standard drug susceptibility testing? Source: International Congress 2018 – Important changes in the management of tuberculosis Year: 2018 First experience with novel molecular diagnostic method for detection of M. tuberculosis and rifampicin resistance Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Advances in the diagnosis of mycobacteria infections and challenges of drug susceptibility testing Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019 Comparison of rapid in-house methods for drug susceptibility testing of mycobacterium tuberculosis with gold standards Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Rapid detection of Mycobacterium tuberculosis from clinical specimens using a new target Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Treatment efficacy of MDR TB based on drug susceptibility testing with microchip technology Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002 Novel biomarker more strongly associated with tuberculosis treatment outcome than conventional or genotypic methods Source: International Congress 2015 – Science and biomarkers in TB Year: 2015 Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods Source: Eur Respir J, 51 (5) 1702189; 10.1183/13993003.02189-2017 Year: 2018 Diagnosis of Mycobacterium tuberculosis drug resistance using molecular genetic methods Source: Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis Year: 2010 Molecular epidemiology of adverse respiratory effects: A high-throughput screening method to detect biomarkers of genotoxic exposure Source: Annual Congress 2010 - Causal factors and mechanisms of outdoor air pollution and nanoparticulates Year: 2010 Non-invasive diagnostics: modern measures for screening and diagnosis Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 An immunochromatographic rapid test for Mycobacterium identification Source: Annual Congress 2010 - What is new in the diagnosis of tuberculosis? Year: 2010 Characterisation of clinical phenotypes is mandatory for the development of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Drug-susceptibility testing in tuberculosis: methods and reliability of results Source: Eur Respir J 2005; 25: 564-569 Year: 2005 Comparative evaluation of the rapid diagnostic assays for detecting tuberculosis (TB) in a reference center for drug resistant TB in Brazil Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Evaluation of new biomarkers for laboratory diagnosis of tuberculosis Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools Year: 2018 Rapid identification of Mycobacterium TB drug resistance: from bench to bedside Source: International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) Year: 2014 Comparison of molecular and immunological methods for a rapid diagnosis of smear-negative tuberculosis Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012 Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for Mycobacterium avium complex disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012